PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21127859-2 2011 dCK phosphorylates and therefore activates nucleoside analogs such as cytarabine, gemcitabine, decitabine, cladribine, and clofarabine that are used routinely in cancer therapy. Nucleosides 43-53 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 0-3 21351740-1 2011 Deoxycytidine kinase (dCK) uses either ATP or UTP as a phosphoryl donor to catalyze the phosphorylation of nucleoside acceptors. Nucleosides 107-117 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 21351740-8 2011 The open dCK conformation is competent for the binding of nucleoside but not for phosphoryl transfer. Nucleosides 58-68 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 9-12 19159229-1 2009 Salvage of nucleosides in the cytosol of human cells is carried out by deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1). Nucleosides 11-22 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 93-96 20080663-2 2010 dCK phosphorylates and therefore activates nucleoside analog prodrugs frequently used in cancer, autoimmunity, and viral infections. Nucleosides 43-53 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 0-3 20080663-9 2010 The severe impact of dCK inactivation on lymphopoiesis was unexpected given that nucleoside salvage has been thought to play a limited, "fine-tuning" role in regulating deoxyribonucleotide triphosphate pools produced by the de novo pathway. Nucleosides 81-91 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 21-24 21362344-1 2011 BACKGROUND: Single nucleotide polymorphisms (SNPs) in the deoxycytidine kinase (dCK) gene are associated with chemosensitivity to nucleoside analogs. Nucleosides 130-140 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 80-83 20957432-3 2010 Field strength, pulse length, temperature, electroporation media, siRNA concentration, among other conditions were tested in order to obtain approximately 70-80% mRNA and enzyme activity downregulation of the cytosolic enzyme deoxycytidine kinase (dCK), necessary for nucleoside analog activation. Nucleosides 268-278 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 248-251 20957432-10 2010 The siRNA transfected cells with reduced dCK expression and activity showed reduced sensitivity to several nucleoside analogs as expected. Nucleosides 107-117 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 41-44 20637175-1 2010 Deoxycytidine kinase (dCK) is a key enzyme in the salvage of deoxynucleosides and in the activation of several anticancer and antiviral nucleoside analogues. Nucleosides 66-76 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 20684612-0 2010 The sugar ring of the nucleoside is required for productive substrate positioning in the active site of human deoxycytidine kinase (dCK): implications for the development of dCK-activated acyclic guanine analogues. Nucleosides 22-32 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 132-135 20684612-0 2010 The sugar ring of the nucleoside is required for productive substrate positioning in the active site of human deoxycytidine kinase (dCK): implications for the development of dCK-activated acyclic guanine analogues. Nucleosides 22-32 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 174-177 20684612-4 2010 Therefore, we crystallized dCK in complex with ACV at the nucleoside phosphoryl acceptor site and UDP at the phosphoryl donor site. Nucleosides 58-68 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 27-30 20684612-7 2010 In comparison to ACV binding to HSV1-TK, in dCK, the nucleoside base adopts a different orientation related by about a 60 degrees rotation. Nucleosides 53-63 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 44-47 20614893-3 2010 This hypothesis is supported by the observation that mutations that enlarge the active site cavity in proximity to the nucleoside 5-position endow dCK with the ability to phosphorylate thymidine. Nucleosides 119-129 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 147-150 19959816-1 2010 Deoxycytidine kinase (dCK) phosphorylates deoxycytidine, deoxyguanosine, and deoxyadenosine and plays an important role in the salvage pathway of nucleoside metabolism. Nucleosides 146-156 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 18974616-1 2008 Deoxycytidine kinase (dCK) is a rate-limiting enzyme in the activation of nucleoside anticancer drugs, such as gemcitabine and cytarabine (Ara-C), to their active metabolites. Nucleosides 74-84 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 18361501-1 2008 Human deoxycytidine kinase (dCK) is responsible for the phosphorylation of a number of clinically important nucleoside analogue prodrugs in addition to its natural substrates, 2"-deoxycytidine, 2"-deoxyguanosine, and 2"-deoxyadenosine. Nucleosides 108-118 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 28-31 18600530-1 2008 Resistance toward nucleoside analogues is often due to decreased activities of the activating enzymes deoxycytidine kinase (dCK) and/or deoxyguanosine kinase (dGK). Nucleosides 18-28 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 124-127 18600530-2 2008 With small interfering RNA (siRNA), dCK and dGK were downregulated by approximately 70% in CEM cells and tested against six nucleoside analogues using the methyl thiazol tetrazolium assay. Nucleosides 124-134 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 36-39 18084067-2 2007 The structures of dCK alone and the dead-end complex of dCK with substrate nucleoside and product ADP or UDP have previously been reported; however, there is currently no structure available for a substrate or product complex. Nucleosides 75-85 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 18-21 18487070-7 2008 EFdA appears to be primarily phosphorylated by the cellular 2"-deoxycytidine kinase (dCK) because: (a) the antiviral activity of EFdA was reduced by the addition of dC, which competes nucleosides phosphorylated by the dCK pathway, (b) the antiviral activity of EFdA was significantly reduced in dCK-deficient HT-1080/Ara-Cr cells, but restored after dCK transduction. Nucleosides 184-195 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 85-88 18084067-2 2007 The structures of dCK alone and the dead-end complex of dCK with substrate nucleoside and product ADP or UDP have previously been reported; however, there is currently no structure available for a substrate or product complex. Nucleosides 75-85 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 56-59 17350163-1 2007 Deoxycytidine kinase (dCK) activates several antileukaemic nucleoside analogues. Nucleosides 59-69 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 17350163-5 2007 These results suggest that activation of dCK via phosphorylation of Ser-74 might constitute a new therapeutic strategy to enhance activation and efficacy of nucleoside analogues. Nucleosides 157-167 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 41-44 16463058-9 2006 CONCLUSIONS: These results show that genetic modifications in non-hematological malignant cells may be associated with resistance to gemcitabine, and that the gene transfer of non-human genes can be used for the reversion of nucleoside analogue resistance due to dCK deficiency. Nucleosides 225-235 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 263-266 17158155-6 2007 The capability of dCK to phosphorylate both D- and L-nucleosides and nucleoside analogs derives from structural properties of both the enzyme and the substrates themselves. Nucleosides 53-63 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 18-21 16936229-5 2006 1-beta-D-Arabinofuranosylcytosine (ara-C), a chemotherapy agent often used in combination with MTX, is a nucleoside analog whose incorporation into chromosome requires prior phosphorylation by dCK. Nucleosides 105-115 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 193-196 12808445-1 2003 Human deoxycytidine kinase (dCK) phosphorylates the natural deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA) and is an essential enzyme for the phosphorylation of numerous nucleoside analog prodrugs routinely used in cancer and antiviral chemotherapy. Nucleosides 69-79 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 28-31 16421443-5 2006 As a purine-nucleoside analog, clofarabine is a better substrate of dCK than deoxycytidine. Nucleosides 12-22 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 68-71 15876539-3 2005 However, there is no crystal structure of dCK with a bound purine nucleoside, although purines are good substrates for dCK. Nucleosides 66-76 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 42-45 15752710-2 2005 Formation of dATP requires phosphorylation of deoxyadenosine by deoxycytidine kinase (dCK), the main nucleoside salvage enzyme in lymphoid cells. Nucleosides 101-111 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 86-89 15571259-1 2004 Recent studies indicate that deoxycytidine kinase (dCK), which activates various nucleoside analogues used in antileukemic therapy, can be regulated by post-translational modification, most probably through reversible phosphorylation. Nucleosides 81-91 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 51-54 15183121-10 2004 Activation of dCK by protein kinase inhibitors and OA was also observed in CCRF-CEM cells and in chronic lymphocytic leukemia B-lymphocytes, suggesting a general mechanism of post-translational regulation of dCK, which could be exploited to enhance the activation of antileukemic nucleoside analogues. Nucleosides 280-290 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 14-17 15183121-10 2004 Activation of dCK by protein kinase inhibitors and OA was also observed in CCRF-CEM cells and in chronic lymphocytic leukemia B-lymphocytes, suggesting a general mechanism of post-translational regulation of dCK, which could be exploited to enhance the activation of antileukemic nucleoside analogues. Nucleosides 280-290 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 208-211 15104248-1 2004 Deoxycytidine kinase (dCK), the principal deoxynucleoside salvage enzyme, plays a seminal role in the bioactivation of a wide array of cytotoxic nucleoside analogues. Nucleosides 47-57 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 12925971-3 2003 A common nucleoside resistance mechanism is mutation affecting the expression or the specificity of dCK. Nucleosides 9-19 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 100-103 12604712-9 2003 These studies indicated that replacement of the 4"-oxygen with sulfur significantly reduced the substrate activity of nucleoside analogs with dCK and that the superior activity of T-araC with respect to araC against solid tumors was not due to superior activity with dCK. Nucleosides 118-128 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 142-145 16533034-1 2006 Human deoxycytidine kinase (dCK) phosphorylates both pyrimidine and purine deoxynucleosides, including numerous nucleoside analogue prodrugs. Nucleosides 80-90 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 28-31 15764852-1 2005 OBJECTIVE: To evaluate whether an inter-individual variability in the activity of thymidine kinase (TK) and deoxycytidine kinase (dCK), which are involved in the first step of phosphorylation of some nucleoside analogues, exists in antiretroviral-naive, HIV-seropositive patients. Nucleosides 200-210 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 130-133 15183121-1 2004 Deoxycytidine kinase (dCK) is a key enzyme in the deoxynucleoside salvage pathway and in the activation of numerous nucleoside analogues used in cancer and antiviral chemotherapy. Nucleosides 55-65 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 15183121-3 2004 Here, we report the effects of a large panel of protein kinase inhibitors on dCK activity in the B-leukemia cell line EHEB, both in basal conditions and in the presence of the nucleoside analogue 2-chloro-2"-deoxyadenosine (CdA) which induces activation of dCK. Nucleosides 176-186 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 77-80 15520873-0 2004 [Special function of deoxycytidine kinase (dCK) in the activation of chemotherapeutic nucleoside analogs and in the inhibition of cell proliferation]. Nucleosides 86-96 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 43-46 15520873-6 2004 In contrast to this, dCK activity was found to be elevated several fold upon short-term treatments of normal human lymphocytes with therapeutic nucleoside analogs, and other genotoxic agents as well as by DNA damaging agents including the DNA polymerase inhibitor aphidicolin, the topoisomerase II inhibitor etoposide and gamma-irradiation, which might be a potentially important phenomenon with respect to the clinical practice, too. Nucleosides 144-154 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 21-24 12429345-2 2002 Earlier studies showed that there are differences in kinetic properties between human and murine dCK, which may explain differences in toxic effects of nucleoside analogs. Nucleosides 152-162 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 97-100 12566083-1 2003 Deoxycytidine kinase (dCK) catalyses the rate-limiting step of the salvage of three natural deoxyribonucleosides as well as several therapeutic nucleoside analogues, which in turn can enhance its enzymatic activity [Biochem Pharmacol 56 (1998) 1175], improving the efficacy of the cytostatic therapy. Nucleosides 101-111 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 12504799-3 2003 The CdA and CAFdA resistant cell lines exhibited increased resistance to the other nucleoside analogues activated by dCK. Nucleosides 83-93 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 117-120 11150511-1 2000 Deoxycytidine kinase (dCK) phosphorylates several anti-cancer and anti-viral nucleoside analogs. Nucleosides 77-87 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 12054684-6 2002 The activity of dCK was decreased in the subline with higher resistance to Ara-G and these cells were highly cross-resistant to other nucleosides activated by dCK. Nucleosides 134-145 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 16-19 12054684-6 2002 The activity of dCK was decreased in the subline with higher resistance to Ara-G and these cells were highly cross-resistant to other nucleosides activated by dCK. Nucleosides 134-145 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 159-162 11896543-1 2002 The relative levels of the deoxycytidine kinase (dCK), deoxyguanosine kinase (dGK), and the 5"-nucleotidase (5"-NT) are of importance for the effect of many nucleoside analogues used in the treatment of hematological malignancies. Nucleosides 157-167 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 49-52 11992640-1 2002 Deoxycytidine kinase (dCK) and deoxycytidine deaminase (dCDA) are two key enzymes in the activation and inactivation, respectively, of deoxycytidine (dCyd) and several chemotherapeutically important nucleoside analogues. Nucleosides 199-209 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 10880764-1 2000 Deoxycytidine kinase (dCK) mediates the phosphorylation of nucleoside analogues that can be used as anti-cancer agents. Nucleosides 59-69 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 11006103-3 2000 Hydroxyurea showed synergistic cytotoxicity with the nucleoside analogs 1-beta-d-arabinofuranosylcytosine and 2-chloro-2"-deoxyadenosine when dCK was expressed in the cytosol or in the nucleus, but not when dCK was expressed in the mitochondria. Nucleosides 53-63 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 142-145 10827186-6 2000 The nucleoside analogs phosphorylated by dCK in the mitochondria were predominantly incorporated into mitochondrial DNA, whereas the nucleoside analogs phosphorylated in the nucleus or cytosol were incorporated into nuclear DNA. Nucleosides 4-14 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 41-44 9804782-1 1998 Deoxycytidine kinase (dCK) catalyzes the rate-limiting step of the deoxynucleoside salvage pathway in mammalian cells and plays a key role in the activation of several pharmacologically important nucleoside analogs. Nucleosides 72-82 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 10499616-7 1999 The relative efficacy of CAFdA as a substrate for purified recombinant deoxycytidine kinase (dCK), the key enzyme in the activation of nucleoside analogues, was very high and exceeded that of CdA as well as the natural substrate, deoxycytidine, by a factor of 2 and 8, respectively. Nucleosides 135-145 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 93-96 10499616-9 1999 Acquired resistance to CAFdA in HL60 and in CCRF-CEM cell lines was directly correlated to the decreased activity of the nucleoside phosphorylating enzyme, dCK. Nucleosides 121-131 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 156-159 10478487-0 1999 Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O"-alkyl analogues. Nucleosides 131-142 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 62-65 10478487-1 1999 Nucleoside analogues with modified sugar moieties have been examined for their substrate/inhibitor specificities towards highly purified deoxycytidine kinase (dCK) and thymidine kinases (tetrameric high-affinity form of TK1, and TK2) from human leukemic spleen. Nucleosides 0-10 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 159-162 7706474-1 1995 Deoxycytidine kinase (dCK) phosphorylates 2"-deoxycytidine, as well as the purine deoxyribonucleosides and a number of nucleoside analogues that are important in the chemotherapy of leukemias. Nucleosides 91-101 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 9598140-1 1998 Substrate/inhibitor specificities of nucleoside analogues with modified sugar moieties toward highly purified deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) from human leukemic spleen have been examined. Nucleosides 37-47 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 132-135 9598144-1 1998 The effect of different nucleoside analogues on deoxycytidine kinase (dCK) and thymidine kinase (TK) was compared in normal human lymphocytes and various leukemic cell lines. Nucleosides 24-34 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 70-73 9598144-8 1998 The possibility of interference of nucleoside analogues with the mechanisms of posttranslational modification of dCK was proposed. Nucleosides 35-45 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 113-116 8625309-1 1996 Deoxycytidine kinase (dCK) phosphorylates a number of nucleoside analogues that are useful in the treatment of various malignancies. Nucleosides 54-64 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 1489095-1 1992 Deoxycytidine kinase (dCK) is necessary for the activity of several nucleosides used for the chemotherapy of cancer and AIDS. Nucleosides 68-79 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 1489095-5 1992 The immunoassay of dCK could prove useful in the selection and monitoring of patients who are being treated with nucleosides that are activated by this enzyme. Nucleosides 113-124 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 19-22 32189555-11 2020 In conclusion TK1 and dCK expression and activity are apparently affected by oxidative stress and treatment by nucleoside analogs. Nucleosides 111-121 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 1406603-9 1992 Of the three nucleoside analogs tested, dFdC was the most efficient dCK substrate. Nucleosides 13-23 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 68-71 32189555-3 2020 Here, we investigated the effects of oxidative stress and nucleoside analog on the expression and activity of TK1 and dCK. Nucleosides 58-68 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 118-121 30539536-6 2019 We have developed a novel SGTC system based on viral vector-mediated delivery of an engineered variant of human deoxycytidine kinase (dCK), which is capable of phosphorylating uridine- and thymidine-based nucleoside analogues that are not substrates for wild-type dCK, such as bromovinyl deoxyuridine (BVdU) and L-deoxythymidine (LdT). Nucleosides 205-215 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 134-137 30539536-6 2019 We have developed a novel SGTC system based on viral vector-mediated delivery of an engineered variant of human deoxycytidine kinase (dCK), which is capable of phosphorylating uridine- and thymidine-based nucleoside analogues that are not substrates for wild-type dCK, such as bromovinyl deoxyuridine (BVdU) and L-deoxythymidine (LdT). Nucleosides 205-215 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 264-267 26620371-1 2016 Deoxycytidine kinase (dCK) (EC 2.7.1.74) is a key enzyme for salvage of deoxynucleosides and activation of numerous anticancer and antiviral nucleoside analogs. Nucleosides 77-87 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 29695239-5 2018 Resistance was shown to be mediated by down-regulation of the deoxycytidine kinase (dCK) protein, responsible for activation of nucleoside analogue prodrugs. Nucleosides 128-138 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 84-87 29393406-1 2018 Deoxycytidine kinase (dCK) is a rate limiting enzyme critical for the phosphorylation of endogenous deoxynucleosides and for the anti-tumor activity of many nucleoside analogs. Nucleosides 105-115 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 29715301-2 2018 dCK is responsible for phosphorylation of deoxycytidine (dC, 2) and other nucleoside analogs, plays a key role in immune activation and has demonstrated to be one of the key enzymes in activating nucleoside based drugs including gemcitabine. Nucleosides 74-84 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 0-3 29715301-2 2018 dCK is responsible for phosphorylation of deoxycytidine (dC, 2) and other nucleoside analogs, plays a key role in immune activation and has demonstrated to be one of the key enzymes in activating nucleoside based drugs including gemcitabine. Nucleosides 196-206 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 0-3 22902741-2 2013 Therefore, a one-step homogeneous assay for real-time determination of TK1 and dCK was developed by combining enzyme complementation with fluorescent signal generation using primer extension and a quenched probe oligodeoxyribonucleotide system at 37 C. Complementation, for producing dCTP and TTP from nucleoside substrates, was carried out by dTMP kinase and/or UMP/CMP kinase and nucleoside diphosphate kinase. Nucleosides 303-313 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 79-82 24462681-1 2014 Deoxycytidine kinase (dCK) is a critical enzyme for activation of anticancer nucleoside analogs. Nucleosides 77-87 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 24419380-1 2014 Deoxycytidine kinase (dCK) is a key enzyme in the nucleoside salvage pathway that is also required for the activation of several anticancer and antiviral nucleoside analog prodrugs. Nucleosides 154-164 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 24419380-5 2014 The structures reveal that the compounds occupy the nucleoside-binding site and bind to the open form of dCK. Nucleosides 52-62 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 105-108 24066967-2 2013 Recent advances in our understanding of the structure and function of deoxycytidine kinase (dCK), a critical enzyme required for the anti-tumor activity for many nucleoside analogs, have clarified the mechanistic role this kinase plays in chemo- and radio-sensitization. Nucleosides 162-172 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 92-95 24066967-4 2013 Since most currently employed nucleoside analogs are primarily activated by dCK, these findings lend fresh impetus to efforts focused on profiling and modulating dCK expression and activity in tumors. Nucleosides 30-40 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 76-79 24066967-4 2013 Since most currently employed nucleoside analogs are primarily activated by dCK, these findings lend fresh impetus to efforts focused on profiling and modulating dCK expression and activity in tumors. Nucleosides 30-40 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 162-165 24066967-5 2013 In this review we will briefly review the pharmacology and biochemistry of the major nucleoside analogs in clinical use that are activated by dCK. Nucleosides 85-95 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 142-145 24419380-1 2014 Deoxycytidine kinase (dCK) is a key enzyme in the nucleoside salvage pathway that is also required for the activation of several anticancer and antiviral nucleoside analog prodrugs. Nucleosides 50-60 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 22850745-1 2012 Deoxycytidine kinase (dCK) is a rate limiting enzyme critical for phosphorylation of endogenous deoxynucleosides for DNA synthesis and exogenous nucleoside analogues for anticancer and antiviral drug actions. Nucleosides 101-111 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 22-25 23230188-4 2012 The nucleoside salvage pathway is dependent on deoxycytidine kinase (dCK) and can be imaged in vivo by PET with 1-(2"-deoxy-2"-[18F]fluoroarabinofuranosyl) cytosine (FAC). Nucleosides 4-14 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 69-72 23148236-3 2012 In this study, we investigate a functional link between nucleotide deficiency, RS, and the nucleoside salvage pathway (NSP) enzymes deoxycytidine kinase (dCK) and thymidine kinase (TK1). Nucleosides 91-101 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 154-157 22927829-4 2012 As a proof of concept we created a library of mutants of the human deoxycytidine kinase (dCK) gene, involved in the activation of nucleoside analogues used in cancer treatment, with the aim of isolating a variant sensitizing cancer cells to the chemotherapy compound Gemcitabine, to be used in gene therapy for anti-cancer approaches or as a poorly immunogenic negative selection marker for cell transplantation approaches. Nucleosides 130-140 Calcium/calmodulin-dependent protein kinase II Drosophila melanogaster 89-92